Back

Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities

3 September 2019 (09:15 - 09:30)
Organised by:
Congress Presentation Part of: New concepts in pulmonary hypertension Pulmonary Hypertension ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Stephan Rosenkranz

Heart Center at the University of Cologne, Cologne (Germany)

5 More presentations in this session

Presentation thumbnail
Validation of ESC/ERS 2015 guidelines risk score in patients with scleroderma associated pulmonary arterial hypertension (SSc-PAH)
Doctor H. Fayed (London, GB)
Abstract Slides Video
Presentation thumbnail
Blood viscosity and its relevance to the diagnosis and management of pulmonary hypertension: a new elephant in the cathlab
Doctor A. Kempny (London, GB)
Abstract Slides Video
Presentation thumbnail
Upfront triple combination therapy with ambrisentan, tadalafil and subcutaneous treprostinil in incident patients with severe pulmonary arterial hypertension
Doctor M. D'Alto (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Waitlist outcomes for Eisenmengers patients listed for bilateral sequential lung transplant or heart-lung transplant
Doctor K. Kearney (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Efficacy of pulmonary hypertension-targeted drugs for severe chronic thromboembolic pulmonary hypertension
Doctor K. Takeuchi (Tokyo, JP)
Abstract Slides Video

Access the full session

Session thumbnail
New concepts in pulmonary hypertension

The Event

Event poster

ESC Congress 2019

3 September 2019 09:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources